Radiomics Compared With Conventional Response Criteria to Predict Progression of Desmoid Tumor After Cryoablation

What this Trial Is About

Desmoid tumors are rare growths that develop from musculoaponeurotic tissues. Although benign, they can cause pain and disability due to their local aggressiveness. Researchers are evaluating how a radiomics approach, which analyzes changes in tumor heterogeneity seen on MRI, compares to conventional methods like RECIST 1.1 in predicting tumor progression after cryoablation treatment for desmoid tumors. The study focuses on patients who have received cryoablation, a procedure that uses repeated cycles of freezing to destroy tumor cells, as their first line treatment for extra-abdominal desmoid tumors. Cryoablation is performed under image guidance and has been shown to be safe for local tumor control. Participants will have baseline MRI scans and clinical and radiologic follow-ups every three months for at least six months or until disease progression or starting new treatment. Participants will undergo regular MRI scans and clinical evaluations to monitor tumor changes and progression using both radiomics and conventional response criteria. The primary outcome is disease progression assessed by mRECIST 1.1 at six months. The study involves careful imaging and clinical follow-up to compare how well radiomics predicts progression compared to standard size-based criteria, with all evaluations performed over a minimum six-month period.

Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation